GRAL — GRAIL Inc.

GRAIL Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $43.6 million, a 14% increase year-over-year.
  • Screening Revenue: $42.3 million (up 34% YoY).
  • Development Services Revenue: $1.3 million (down 49% YoY).
• Full Year 2025 Revenue: $147.2 million, a 17% increase from 2024.
  • Screening Revenue: $138.6 million (up 28% YoY).
  • U.S. Galleri Revenue: $136.8 million (up 26% YoY).
• Net Loss: $99.2 million for Q4 2025 (up 2% YoY), and $408.4 million for the full year (improved by 80% YoY).
• Non-GAAP Adjusted Gross Profit: Q4 at $23.1 million (up 29% YoY); full year at $73.6 million (up 27% YoY).
• Adjusted EBITDA: Q4 at -$71.8 million (improved by 15% YoY); full year at -$320.6 million (improved by 34% YoY).
• Cash Position: $904.4 million at year-end, bolstered by equity placements.

2. Strategic Updates and Business Highlights

• GRAIL reported significant commercial growth in 2025, with Galleri test volume increasing by 36% to over 185,000 tests.
• The company announced plans to expand its field sales and medical teams to drive further commercial momentum.
• Positive results from the NHS-Galleri trial indicated a fourfold increase in cancer detection rates and a reduction in Stage IV cancer diagnoses, although the primary endpoint was not met.
• GRAIL completed its PMA submission to the FDA for Galleri, marking a critical step towards broader access.
• The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was passed, establishing a pathway for Medicare coverage of FDA-approved tests.

3. Forward Guidance and Outlook

• GRAIL reiterated its sales growth guidance for Galleri in 2026, projecting a 22% to 32% increase.
• Expected cash burn for 2026 is capped at $300 million, with a cash runway extending into 2030.
• The company anticipates presenting full data from the NHS-Galleri and PATHFINDER 2 studies in mid-2026.

4. Bad News, Challenges, or Points of Concern

• The NHS-Galleri trial did not meet its primary endpoint of statistically significant reduction in combined Stage III and IV cancer diagnoses, which raised concerns about the impact on FDA approval and Medicare coverage.
• Development services revenue saw a significant decline, indicating potential challenges in that segment.
• The company faces scrutiny regarding the implications of the trial results on future studies and regulatory approvals, particularly concerning the REACH study and Medicare coverage.

5. Notable Q&A Insights

• Management confirmed that the probability of FDA approval remains unchanged despite missing the primary endpoint in the NHS-Galleri trial.
• There was discussion around the potential impact of the NHS-Galleri results on the Medicare REACH study, with management expressing optimism about the study's design and power.
• The company plans to extend follow-up data collection from the NHS-Galleri trial by 6 to 12 months to better assess outcomes.
• Management emphasized the importance of the substantial reduction in Stage IV cancers and the fourfold increase in detection rates as compelling evidence for clinicians and payers.
• There was acknowledgment that the design of the NHS-Galleri trial may have benefited from a longer follow-up period, which is now being addressed through extended data collection.

Overall, GRAIL's Q4 2025 earnings call highlighted strong financial growth and strategic advancements, tempered by challenges related to trial outcomes and regulatory scrutiny.